SynthesisBritish journal of cancer2003
The role of HER-2/neu expression on the survival of patients with lung cancer: a systematic review of the literature.
Synthesis in British journal of cancer, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 5 syntheses or guidelines pooled it, 113 citations in OpenAlex.
- Prognostic significance of preoperative serum carcinoembryonic antigen in non-small cell lung cancer: a meta-analysis.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Pooled it
- Lymphatic microvessel density as a prognostic factor in non-small cell lung carcinoma: a meta-analysis of the literature.Molecular biology reports · 2012Pooled it
- Has Cox-2 a prognostic role in non-small-cell lung cancer? A systematic review of the literature with meta-analysis of the survival results.British journal of cancer · 2006Pooled it
- The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis.British journal of cancer · 2005Pooled it
- Ki-67 expression and patients survival in lung cancer: systematic review of the literature with meta-analysis.British journal of cancer · 2004Pooled it
- Evolving treatment strategies for HER2-altered non-small-cell lung cancer: the rise of TKIs and ADCs.Frontiers in oncology · 2026Review
- Chemotherapeutic Activity of Imidazolium-Supported Pd(II)Pharmaceuticals (Basel, Switzerland) · 2023Article
- HER-2-targeted boron neutron capture therapy using an antibody-conjugated boron nitride nanotube/β-1,3-glucan complex.Nanoscale advances · 2023Article
- Primary Lung Cancer After Treatment for Breast Cancer.International journal of women's health · 2021Review
- The prognostic factors of recurrence and survival in female patients with lung adenocarcinoma and breast cancer.Journal of cancer research and clinical oncology · 2020Article
- Female reproductive factors and the risk of lung cancer in postmenopausal women: a nationwide cohort study.British journal of cancer · 2020Article
- YES1 activation induces acquired resistance to neratinib in HER2-amplified breast and lung cancers.Cancer science · 2020Article
- Smoking, Sex, and Non-Small Cell Lung Cancer: Steroid Hormone Receptors in Tumor Tissue (S0424).Journal of the National Cancer Institute · 2018Article
- Synthesis and anticancer activity of new quinazoline derivatives.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2017Article
- Epidemiological study of HER-2 mutations among EGFR wild-type lung adenocarcinoma patients in China.BMC cancer · 2016Article
- The role of SOX-2 on the survival of patients with non-small cell lung cancer.Journal of thoracic disease · 2015Article
- Study on extracellular matrix metalloproteinase inducer and human epidermal growth factor receptor-2 protein expression in papillary thyroid carcinoma using a quantum dot-based immunofluorescence technique.Experimental and therapeutic medicine · 2015Article
- PD-L1 over-expression and survival in patients with non-small cell lung cancer: a meta-analysis.Translational lung cancer research · 2015Article
- HER2 expression in gastric and oesophageal cancer: a meta-analytic review.Journal of gastrointestinal oncology · 2015Article
- Sunlight may increase the FDG uptake value in primary tumors of patients with non-small cell lung cancer.Oncology letters · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
C-erbB-2 prognostic value for survival in patients with lung cancer remains controversial. We performed a systematic review of the literature to clarify its impact. Studies were identified by an electronic search in order to aggregate the survival results, after a methodological assessment using the scale of the European Lung Cancer Working Party. To be eligible, a study had to deal with c-erbB-2 assessment in lung cancer patients and to analyse survival according to c-erbB-2 expression. In total, 30 studies were eligible: 24 studies dealt with non-small-cell lung carcinoma (NSCLC), five with adenocarcinoma and one study dealt with small-cell carcinoma. In all, 31% of the patients were positive for c-erbB-2. According to c-erbB-2 expression, 13 studies were 'negative' (significant detrimental effect on survival), one 'positive' (significant survival improvement) and 16 not significant. Significant studies had a better subscore relative to analysis and results report than nonsignificant studies. In total, 86% of the significant studies and only 56% of the nonsignificant studies were evaluable for the meta-analysis. This suggests a possible bias in our aggregated results. For NSCLC, the hazard ratio was 1.55 (95% CI: 1.29-1.86) in favour of tumours that do not express c-erbB-2. In conclusion, the overexpression of c-erbB-2 might be a factor of poor prognosis for survival in NSCLC, but there is a potential bias in favour of the significant studies with an overestimation risk of the magnitude of the true effect of c-erbB-2 overexpression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.